22 sept 2013

FINAL CliNK MEETING, JUNE 17-18, 2013

The last CliNK meeting took place in Madrid on 17-18 June.
Organized by Carlos Vilches, from Hospital Puerta de Hierro.
The last CliNK meeting took place in Madrid on 17-18 June, organized by Carlos Vilches, from Hospital Puerta de Hierro. 

Monday

1. After opening of the meeting and welcome by the organizer, the coordinator, Alberto Anel, on behalf of Oswaldo Somolinos, informed the group of the next administrative steps and actions to be taken, and of the end of the project by June 30th. A general perspective of the goals achieved was also provided. This led to a series of talks by each group, on different topics related to the project objectives:

2. Martín Villalba reviewed the different surface markers used historically for evaluating NK-cell activation and presented original results on NK-cell expression of different isoforms of the leukocyte receptor CD45 and correlation of these with their activation state.

3. Anne Marie Caminade reviewed the structure of dendrimers and presented the procedures for assessing their purity and possible degradation in different physical and chemical conditions, using equipment obtained thanks to this project. She also clarified practical question from participants regarding stability of the dendrimers in different storage conditions.

4. Miguel López-Botet summarized the preliminary results of a study of NK-cell receptor profiles in two cohorts of patients submitted by the Montpellier group: ones suffering Epstein-Barr virus reactivation in the context of post-transplant immunosuppression; and long-term survivals of different malignancies.

5. Alberto Anel presented an evaluation of the cytotoxic activityy exerted by NK cells expanded using different protocols (with/without cytokines and/or EBV+ cell lines).

6. Carlos Vilches listed previous results of his group that would not be recapitulated, and introduced the different topics that would be presented by group members and himself.

7. Elisa Cisneros showed an analysis of the distribution of KIR-gene haplotypes in Spaniards, as an example of a South European population. The results included the frequencies of common arrangements of the KIR complex, as well as of certain recombinants; many of these, characterized by the group, including a novel chimeric receptor combining domains of an inhibitory and an activating KIR.

Tuesday

1. Aura Muntasell presented her results on the effect of copy-number variation of the NKG2C gene on NK-cell phenotype (correlation with proportion of NKG2C+ cells and receptor density on the cell surface) and function (Ca2+ influx and proliferative response to cytokines and receptor crosslinking). She also presented a study correlating NK-cell phenotype and antibody-mediated NK-cell cytotoxicity (ADCC) against cytomegalovirus-infected fibroblasts.

2. Julián Pardo summarized an evaluation of cytotoxicity mediated by NK cells against cells from chronic lymphocytic leukemia patients, Key points of this study are proper existence of such activity, under-estimated in previous studies by other groups; and rough correlation between the degree of cytotoxicity and genetic disparity between effector and target cells according to the missing-self model, evaluated in collaboration with the Majadahonda group. Alternative strategies for a second, confirmatory set of experiments were discussed.

3. Elisa Cisneros presented a summary of polymorphism of the orphan KIR2DL5A receptor, the different phenotypes conferred by its alleles, and the experimental approach she is undertaking to identify the molecular mechanisms hidden underneath those phenotypes.

4. Carlos Vilches recapitulated historical contributions of the Majadahonda group to current knowledge on HLA-C molecules (whose expression controls much of NK-cell activity through recognition by multiple KIR), and presented a novel method developed in the laboratory to facilitate isolation of the whole HLA-C gene in an allele-specific manner. He also presented recent advances of the group in the search for ligands for KIR of unknown specificity.

5. Manuela Moraru presented original results on HSV-1 infection that reveal an epistatic interaction between a functional polymorphism in the CD16A molecule that mediates ADCC and a polymorphism of human IgG1. The two polymorphisms modulate affinity of the immunoglobulin for cellular and viral receptors for IgG. Preliminary results of ongoing functional studies are in support of the observed genetic interaction.

After general discussion of experimental approaches to address questions raised during the different talks, Alberto Anel reviewed the essential contributions achieved through networking within the CliNK project, presented an estimation of the timeframe for future Interreg-SUDOE calls and surveyed participants on their interest and proposals for possible participation in the next call. The idea was favorably received in general terms, and different possibilities were presented and discussed.

After closure of the meeting and lunch, several members of the consortium held smaller informal meetings to discuss the details of ongoing and future collaborations.

2 feb 2013

Publicaciones conjuntas de los grupos de CliNK

Protein Kinase C-theta (PKC-theta) in Natural Killer Cell Function and Anti-Tumor Immunity
Anel A, Aguiló JI, Catalán E, Garaude J, Rathore MG, Pardo J, Villalba M.

Front Immunol. 2012;3:187.

Influence of congenital human cytomegalovirus infection and the NKG2C genotype on NK-cell subset distribution in children.
Noyola DE, Fortuny C, Muntasell A, Noguera-Julian A, Muñoz-Almagro C, Alarcón A, Juncosa T, Moraru M, Vilches C, López-Botet M.

Eur J Immunol. 2012 Dec;42(12):3256-66

KIR2DL5: An Orphan Inhibitory Receptor Displaying Complex Patterns of Polymorphism and Expression.
Cisneros E, Moraru M, Gómez-Lozano N, López-Botet M, Vilches C.

Front Immunol. 2012;3:289

Assessment of copy-number variation in the NKG2C receptor gene in a single-tube and characterization of a reference cell panel, using standard polymerase chain reaction.
Moraru M, Cañizares M, Muntasell A, de Pablo R, López-Botet M, Vilches C.

Tissue Antigens. 2012 Aug;80(2):184-7

Host genetic factors in susceptibility to herpes simplex type 1 virus infection: contribution of polymorphic genes at the interface of innate and adaptive immunity.
Moraru M, Cisneros E, Gómez-Lozano N, de Pablo R, Portero F, Cañizares M, Vaquero M, Roustán G, Millán I, López-Botet M, Vilches C.

J Immunol. 2012 May 1;188(9):4412-20.

The NF-kappaB member p65 controls glutamine metabolism through miR-23a..
Rathore MG, Saumet A, Rossi JF, de Bettignies C, Tempé D, Lecellier CH, Villalba M.

Int J Biochem Cell Biol. 2012 Sep;44(9):1448-56.

Publicaciones del Grupo de Alberto Anel

Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells.
De Miguel D, Basanez G, Sánchez D, Galán-Malo P, Marzo I, Larrad L, Naval J, Pardo J, Anel A, Martinez-Lostao L.

Mol Pharm. 2013 Jan 18. [Epub ahead of print]

Protein Kinase C-θ (PKC-θ) in Natural Killer Cell Function and Anti-Tumor Immunity.
Anel A, Aguiló JI, Catalán E, Garaude J, Rathore MG, Pardo J, Villalba M.

Front Immunol. 2012;3:187. doi: 10.3389/fimmu.2012.00187. Epub 2012 Jul 5.

Cytotoxicity of quinone drugs on highly proliferative human leukemia T cells: reactive oxygen species generation and inactive shortened SOD1 isoform implications.
Aguiló JI, Iturralde M, Monleón I, Iñarrea P, Pardo J, Martínez-Lorenzo MJ, Anel A, Alava MA.

Chem Biol Interact. 2012 Jun 25;198(1-3):18-28. doi: 10.1016/j.cbi.2012.05.001. Epub 2012 May 16.

Targeting the Apo2L/TRAIL system for the therapy of autoimmune diseases and cancer.
Martinez-Lostao L, Marzo I, Anel A, Naval J.

Biochem Pharmacol. 2012 Jun 1;83(11):1475-83. doi: 10.1016/j.bcp.2011.12.036. Epub 2012 Jan 2. Review.


APO2L/TRAIL: new insights in the treatment of autoimmune disorders.
Anel A, Martinez-Lostao L.

Recent Pat Inflamm Allergy Drug Discov. 2011 Sep;5(3):184-99. Review.


Phenotypic and functional evaluation of CD3+CD4-CD8- T cells in human CD8 immunodeficiency.
Bernardo I, Mancebo E, Aguiló I, Anel A, Allende LM, Guerra-Vales JM, Ruiz-Contreras J, Serrano A, Talayero P, de la Calle O, Gonzalez-Santesteban C, Paz-Artal E.

Haematologica. 2011 Aug;96(8):1195-203. doi: 10.3324/haematol.2011.041301. Epub 2011 May 5.

Publicaciones del Grupo de Julián Pardo

Antitumor Immunotherapeutic and Toxic Properties of an HDL-Conjugated Chimeric IL-15 Fusion Protein.
Ochoa MC, Fioravanti J, Rodriguez I, Hervas-Stubbs S, Azpilikueta A, Mazzolini G, Gúrpide A, Prieto J, Pardo J, Berraondo P, Melero I.
Cancer Res. 2013 Jan 1;73(1):139-49.

Blinking effect and the use of quantum dots in single molecule spectroscopy.
Rombach-Riegraf V, Oswald P, Bienert R, Petersen J, Domingo MP, Pardo J, Gräber P, Galvez EM.

Biochem Biophys Res Commun. 2013 Jan 4;430(1):260-4.

Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell death.
Aporta A, Arbues A, Aguilo JI, Monzon M, Badiola JJ, de Martino A, Ferrer N, Marinova D, Anel A, Martin C, Pardo J.

PLoS One. 2012;7(9):e45213.

Bis(methyl)gliotoxin proves to be a more stable and reliable marker for invasive aspergillosis than gliotoxin and suitable for use in diagnosis.
Domingo MP, Colmenarejo C, Martínez-Lostao L, Müllbacher A, Jarne C, Revillo MJ, Delgado P, Roc L, Meis JF, Rezusta A, Pardo J, Gálvez EM.

Diagn Microbiol Infect Dis. 2012 May;73(1):57-64.

Protein oligomerization mediated by the transmembrane carboxyl terminal domain of Bcl-XL.
Ospina A, Lagunas-Martínez A, Pardo J, Carrodeguas JA.

FEBS Lett. 2011 Oct 3;585(19):2935-42.

Course of infection with the emergent pathogen Brucella microti 
in immunocompromised mice.
Jiménez de Bagüés MP, de Martino A, Quintana JF,Alcaraz A,Pardo J.

Infect Immun. 2011 Oct;79(10):3934-9.

MAGUKs, scaffolding proteins at cell junctions, are substrates of different proteases during apoptosis.
Ivanova S, Gregorc U, Vidergar N, Javier R, Bredt DS, Vandenabeele P, Pardo J, Simon MM, Turk V, Banks L, Turk B.

Cell Death Dis. 2011 Jan 20;2:e116.

Mouse granzyme K has pro-inflammatory potential.
Joeckel LT, Wallich R, Martin P, Sanchez-Martinez D, Weber FC, Martin SF, Borner C, Pardo J, Froelich C, Simon MM.

Cell Death Differ. 2011 Jul;18(7):1112-9.

Perforin rapidly induces plasma membrane phospholipid flip-flop.
Metkar SS, Wang B, Catalan E, Anderluh G, Gilbert RJ, Pardo J, Froelich CJ.

PLoS One. 2011;6(9):e24286.

Publicaciones del Grupo de Isabel Marzo y Javier Naval

Direct interaction of Bax and Bak with Bcl-2 Homology domain-3 (BH3)-only proteins in living cells revealed by fluorescence complementation.
Vela L, Gonzalo O, Naval J, Marzo I.

J Biol Chem. 2013 Jan 2. [Epub ahead of print]

Organometallic Palladium Complexes with a Water-Soluble Iminophosphorane Ligand as Potential Anticancer Agents.
Carreira M, Calvo-Sanjuán R, Sanaú M, Marzo I, Contel M.

Organometallics. 2012 Aug 27;31(16):5772-5781.

Cytotoxic hydrophillic iminpphosphorane coordination compounds of d8 metals. Studies of their interaction with DNA and HSA.
Carreira M, Calvo-Sanjuán, R, Sanaú, M, Zhao, X, Magliozzo, RS, Marzo, I, Contel, M

J Inorg Biochem. 2012 Nov;116:204-14.

Cell fate after mitotic arrest in different tumor cells is determined by the balance between slippage and apoptotic threshold.
Galán-Malo P, Vela L, Gonzalo O, Calvo-Sanjuán R, Gracia-Fleta L, Naval J, Marzo I.

Toxicol Appl Pharmacol. 2012 Feb 1;258(3):384-93.

Bortezomib resistance in a myeloma cell line is associated to PSM5 overexpression and polyploidy.
Balsas P, Galán-Malo P, Marzo I, Naval J.

Leuk Res. 2012 Feb;36(2):212-8.

Iminophosphorane-organogold(III) complexes induce cell death through mitochondrial ROS production.
Vela L, Contel M, Palomera L, Azaceta G, Marzo I.

J Inorg Biochem. 2011 Oct;105(10):1306-1

Publicaciones del Grupo de Anne Marie Caminade

Effect of viologen-phosphorus dendrimers on acetylcholinesterase and butyrylcholinesterase activities.
Ciepluch K, Weber M, Katir N, Caminade AM, El Kadib A, Klajnert B, Majoral JP, Bryszewska M.

Int J Biol Macromol. 2012 Dec 10;54C:119-124.

Organophosphorus chemistry for the synthesis of dendrimers.
Caminade AM, Laurent R, Zablocka M, Majoral JP.

Molecules. 2012 Nov 16;17(11):13605-21.

From graftable biphotonic chromophores to water-soluble organic nanodots for biophotonics: the importance of environmental effects.
Rouxel C, Charlot M, Mongin O, Krishna TR, Caminade AM, Majoral JP, Blanchard-Desce M.

Chemistry. 2012 Dec 14;18(51):16450-62.

Cytotoxicity and genotoxicity of cationic phosphorus-containing dendrimers.
Gomulak P, Klajnert B, Bryszewska M, Majoral JP, Caminade AM, Blasiak J.

Curr Med Chem. 2012 Dec 1;19(36):6233-40.

Validation of a generation 4 phosphorus-containing polycationic dendrimer for gene delivery against HIV-1.
Briz V, Serramía MJ, Madrid R, Hameau A, Caminade AM, Majoral JP, Muñoz-Fernández MA.

Curr Med Chem. 2012;19(29):5044-51.

Dendritic phosphoramidite ligands for Rh-catalyzed [2+2+2] cycloaddition reactions: unprecedented enhancement of enantiodiscrimination.
Garcia L, Roglans A, Laurent R, Majoral JP, Pla-Quintana A, Caminade AM.

Chem Commun (Camb). 2012 Sep 25;48(74):9248-50.

Organocatalysis with dendrimers.
Caminade AM, Ouali A, Keller M, Majoral JP.

Chem Soc Rev. 2012 Jun 7;41(11):4113-25.

DFT study of structure, IR and Raman spectra of the first generation dendron built from cyclotriphosphazene core with terminal carbamate and ester groups.
Furer VL, Vandyukov AE, Fuchs S, Majoral JP, Caminade AM, Kovalenko VI.

Spectrochim Acta A Mol Biomol Spectrosc. 2012 Jun;91:97-105.

Phosphorus-containing dendrimers against α-synuclein fibril formation.
Milowska K, Gabryelak T, Bryszewska M, Caminade AM, Majoral JP.

Int J Biol Macromol. 2012 May 1;50(4):1138-43.

Synthesis of dye/fluorescent functionalized dendrons based on cyclotriphosphazene.
Hameau A, Fuchs S, Laurent R, Majoral JP, Caminade AM.

Beilstein J Org Chem. 2011;7:1577-83.

Biological properties of new viologen-phosphorus dendrimers.
Ciepluch K, Katir N, El Kadib A, Felczak A, Zawadzka K, Weber M, Klajnert B, Lisowska K, Caminade AM, Bousmina M, Bryszewska M, Majoral JP.

Mol Pharm. 2012 Mar 5;9(3):448-57.

Phosphorus dendrimers affect Alzheimer's (Abeta1-28) peptide and MAP-Tau protein aggregation.
Wasiak T, Ionov M, Nieznanski K, Nieznanska H, Klementieva O, Granell M, Cladera J, Majoral JP, Caminade AM, Klajnert B.

Mol Pharm. 2012 Mar 5;9(3):458-69.

Hierarchically porous nanostructures through phosphonate-metal alkoxide condensation and growth using functionalized dendrimeric building blocks.
Brahmi Y, Katir N, Hameau A, Essoumhi A, Essassi el M, Caminade AM, Bousmina M, Majoral JP, El Kadib A.

Chem Commun (Camb). 2011 Aug 14;47(30):8626-8.

Specific vapor sorption properties of phosphorus-containing dendrimers.
Gerasimov AV, Ziganshin MA, Vandyukov AE, Kovalenko VI, Gorbatchuk VV, Caminade AM, Majoral JP.

J Colloid Interface Sci. 2011 Aug 1;360(1):204-10.

A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis.
Hayder M, Poupot M, Baron M, Nigon D, Turrin CO, Caminade AM, Majoral JP, Eisenberg RA, Fournié JJ, Cantagrel A, Poupot R, Davignon JL.

Sci Transl Med. 2011 May 4;3(81):81ra35.

Nanostructuring polymeric materials by templating strategies.
Knoll W, Caminade AM, Char K, Duran H, Feng CL, Gitsas A, Kim DH, Lau A, Lazzara TD, Majoral JP, Steinhart M, Yameen B, Zhong XH.

Small. 2011 May 23;7(10):1384-91.

Vibrational spectra study of fluorescent dendrimers built from the cyclotriphosphazene core with terminal dansyl and carbamate groups.
Furer VL, Vandyukova II, Vandyukov AE, Fuchs S, Majoral JP, Caminade AM, Kovalenko VI.

Spectrochim Acta A Mol Biomol Spectrosc. 2011 Aug;79(3):462-70.

Fluorescent core-shell star polymers based bioassays for ultrasensitive DNA detection by surface plasmon fluorescence spectroscopy.
Feng CL, Yin M, Zhang D, Zhu S, Caminade AM, Majoral JP, Müllen K.

Macromol Rapid Commun. 2011 Apr 19;32(8):679-83.

Publicaciones del Grupo de Miguel López-Botet

CMV and Immunosenescence: from basics to clinics.
Solana R, Tarazona R, Aiello AE, Akbar AN, Appay V, Beswick M, Bosch JA, Campos C, Cantisán S, Cicin-Sain L, Derhovanessian E, Ferrando-Martínez S, Frasca D, Fulöp T, Govind S, Grubeck-Loebenstein B, Hill A, Hurme M, Kern F, Larbi A, López-Botet M, et al.

Immun Ageing. 2012 Oct 31;9(1):23.

Functional impact of A91V mutation of the PRF1 perforin gene.
Martínez-Pomar N, Lanio N, Romo N, Lopez-Botet M, Matamoros N.

Hum Immunol. 2013 Jan;74(1):14-7.

Influence of congenital human cytomegalovirus infection and the NKG2C genotype on NK-cell subset distribution in children.
Noyola DE, Fortuny C, Muntasell A, Noguera-Julian A, Muñoz-Almagro C, Alarcón A, Juncosa T, Moraru M, Vilches C, López-Botet M.

Eur J Immunol. 2012 Dec;42(12):3256-66

The human cytomegalovirus-specific UL1 gene encodes a late-phase glycoprotein incorporated in the virion envelope.
Shikhagaie M, Mercé-Maldonado E, Isern E, Muntasell A, Albà MM, López-Botet M, Hengel H, Angulo A.

J Virol. 2012 Apr;86(8):4091-101.

Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis.
Martínez-Rodríguez JE, López-Botet M, Munteis E, Rio J, Roquer J, Montalban X, Comabella M.

Clin Immunol. 2011 Dec;141(3):348-56.

Association of atherosclerosis with expression of the LILRB1 receptor by human NK and T-cells supports the infectious burden hypothesis.
Romo N, Fitó M, Gumá M, Sala J, García C, Ramos R, Muntasell A, Masiá R, Bruguera J, Subirana I, Vila J, de Groot E, Elosua R, Marrugat J, López-Botet M.

Arterioscler Thromb Vasc Biol. 2011 Oct;31(10):2314-21.

Natural killer cell-mediated response to human cytomegalovirus-infected macrophages is modulated by their functional polarization.
Romo N, Magri G, Muntasell A, Heredia G, Baía D, Angulo A, Guma M, López-Botet M.

J Leukoc Biol. 2011 Oct;90(4):717-26.

MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine.
Bousquet J, Anto J, Auffray C, Akdis M, Cambon-Thomsen A, Keil T, Haahtela T, Lambrecht BN, Postma DS, Sunyer J, Valenta R,...Lopez-Botet M, et al.

Allergy. 2011 May;66(5):596-604.

Natural killer cell receptor expression reflects the role of human cytomegalovirus in the pathogenesis of a subset of CD4+ T-cell large granular lymphocytosis.
Sáez-Borderías A, Romo N, Ruiz-Cabello F, Cantón J, Tielemans D, Langerak AW, López-Botet M.

Hum Immunol. 2011 Mar;72(3):226-8

NKp46 and DNAM-1 NK-cell receptors drive the response to human cytomegalovirus-infected myeloid dendritic cells overcoming viral immune evasion strategies.
Magri G, Muntasell A, Romo N, Sáez-Borderías A, Pende D, Geraghty DE, Hengel H, Angulo A, Moretta A, López-Botet M.

Blood. 2011 Jan 20;117(3):848-56

Publicaciones del Grupo de Jean François Rossi

Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
Caraux A, Vincent L, Bouhya S, Quittet P, Moreaux J, Requirand G, Veyrune JL, Olivier G, Cartron G, Rossi JF, Klein B.

Oncotarget. 2012 Nov;3(11):1335-47.

Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.
Kassambara A, Hose D, Moreaux J, Rème T, Torrent J, Rossi JF, Goldschmidt H, Klein B.

PLoS One. 2012;7(7):e42161.

A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.
Morschhauser F, Recher C, Milpied N, Gressin R, Salles G, Brice P, Vey N, Haioun C, Colombat P, Rossi JF, Deconinck E, Lazreg F, Bergougnoux L, Delsol G, Attal M.

Ann Oncol. 2012 Oct;23(10):2687-95.

Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis.
Auger S, Duny Y, Rossi JF, Quittet P.

Br J Haematol. 2012 Aug;158(3):386-98.

Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program.
Khellaf M, Michel M, Quittet P, Viallard JF, Alexis M, Roudot-Thoraval F, Cheze S, Durand JM, Lefrère F, Galicier L, Lambotte O, Panelatti G, Slama B, Damaj G, Sebahoun G, Gyan E, Delbrel X, Dhedin N, Royer B, Schleinitz N, Rossi JF, Mahévas M, Languille L, Bierling P, Godeau B.

Blood. 2011 Oct 20;118(16):4338-45.

Phase I study of atacicept in relapsed/refractory multiple myeloma (MM) and Waldenström's macroglobulinemia.
Rossi JF.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):136-8

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, Tilly H, Morschhauser F, Thieblemont C, Ysebaert L, Devidas A, Petit B, de Leval L, Gaulard P, Feuillard J, Bordessoule D, Hermine O; GELA and GOELAMS Intergroup.

Blood. 2011 Feb 10;117(6):1834-9

T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS, Klein B, Fiol G, Rossi JF.

Haematologica. 2011 Mar;96(3):400-7.

Mobilization of plasma cells in healthy individuals treated with granulocyte colony-stimulating factor for haematopoietic stem cell collection.
Caraux A, Perez-Andres M, Larroque M, Requirand G, Lu ZY, Kanouni T, Rossi JF, Orfao A, Klein B.

Immunology. 2011 Feb;132(2):266-72.

Publicaciones del Grupo de Carlos Vilches

KIR2DL5: An Orphan Inhibitory Receptor Displaying Complex Patterns of Polymorphism and Expression.
Cisneros E, Moraru M, Gómez-Lozano N, López-Botet M, Vilches C.

Front Immunol. 2012;3:289

Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860.
Cisneros E, Baños I, Citores MJ, Duca A, Salas C, Noblejas A, Cañizares M, Millán I, Cuervas-Mons V, Vilches C.

Transplantation. 2012 Aug 15;94(3):275-80.

Assessment of copy-number variation in the NKG2C receptor gene in a single-tube and characterization of a reference cell panel, using standard polymerase chain reaction.
Moraru M, Cañizares M, Muntasell A, de Pablo R, López-Botet M, Vilches C.

Tissue Antigens. 2012 Aug;80(2):184-7.

KIR typing by non-sequencing methods: polymerase-chain reaction with sequence-specific primers.
Ordóñez D, Moraru M, Gómez-Lozano N, Cisneros E, Vilches C.

Methods Mol Biol. 2012;882:415-30.

Host genetic factors in susceptibility to herpes simplex type 1 virus infection: contribution of polymorphic genes at the interface of innate and adaptive immunity.
Moraru M, Cisneros E, Gómez-Lozano N, de Pablo R, Portero F, Cañizares M, Vaquero M, Roustán G, Millán I, López-Botet M, Vilches C.

J Immunol. 2012 May 1;188(9):4412-20.

Allele-specific amplification of the complete HLA-C gene from genomic DNA - a novel Cw4 allele (C*04:71) with a Cw1 motif in the peptide-binding site.
Moraru M, Balas A, de Pablo R, Vicario JL, Vilches C.

Tissue Antigens. 2012 Apr;79(4):291-4.

Multiple viral ligands naturally presented by different class I molecules in transporter antigen processing-deficient vaccinia virus-infected cells.
Lorente E, Infantes S, Barnea E, Beer I, García R, Lasala F, Jiménez M, Vilches C, Lemonnier FA, Admon A, López D.

J Virol. 2012 Jan;86(1):527-41

Genetic basis of end-stage hypertrophic cardiomyopathy.
Garcia-Pavia P, Vázquez ME, Segovia J, Salas C, Avellana P, Gómez-Bueno M, Vilches C, Gallardo ME, Garesse R, Molano J, Bornstein B, Alonso-Pulpon L.

Eur J Heart Fail. 2011 Nov;13(11):1193-201

Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: a clinicopathological study.
Garcia-Pavia P, Syrris P, Salas C, Evans A, Mirelis JG, Cobo-Marcos M, Vilches C, Bornstein B, Segovia J, Alonso-Pulpon L, Elliott PM.

Heart. 2011 Nov;97(21):1744-52

Mitochondrial haplogroups associated with end-stage heart failure and coronary allograft vasculopathy in heart transplant patients.
Gallardo ME, García-Pavía P, Chamorro R, Vázquez ME, Gómez-Bueno M, Millán I, Almoguera B, Domingo V, Segovia J, Vilches C, Alonso-Pulpón L, Garesse R, Bornstein B.

Eur Heart J. 2012 Feb;33(3):346-53.

Molecular characterisation of KIR2DS2*005, a fusion gene associated with a shortened KIR haplotype.
Ordóñez D, Gómez-Lozano N, Rosales L, Vilches C.

Genes Immun. 2011 Oct;12(7):544-51.

Publicaciones del Grupo de Martín Villalba

The protooncogene Vav1 regulates murine leukemia virus-induced T-cell leukemogenesis.
Kaminski S, Adjali O, Jacquet C, Garaude J, Keriel A, Lassaux A, Hipskind R, Sitbon M, Taylor N, Villalba M.

Oncoimmunology. 2012 Aug 1;1(5):600-608.

The NF-kappaB member p65 controls glutamine metabolism through miR-23a.
Rathore MG, Saumet A, Rossi JF, de Bettignies C, Tempé D, Lecellier CH, Villalba M.

Int J Biochem Cell Biol. 2012 Sep;44(9):1448-56.

From tumor cell metabolism to tumor immune escape.
Villalba M, Rathore MG, Lopez-Royuela N, Krzywinska E, Garaude J, Allende-Vega N.

Int J Biochem Cell Biol. 2013 Jan;45(1):106-13.

9 oct 2012

Active participation of CliNK at the 3rd European Immunology Congress

As timely posted in our Web and Facebook page, several members of CliNK actively participated in the 3rd European Congress of Immunology (ECI), celebrated in Glasgow from the 5th to 9th September.

25 jun 2012

The 4th CliNK Meeting Summary

The 4th CliNK meeting was held in Toulouse on the 18th and 19th June 2012.


After the welcome by the organizer, Anne Marie Caminade, Remy Poupot, collaborator of Dr. Caminade at Toulouse, explained the details about using dendrimers to activate NK cells and their applications also to inflammatory diseases such as rheumatoid arthritis.

Next, Alberto Anel gave administrative and communication news from the administrator and the communication manager, and showed data on the use of different cytokine combinations and different feeder cells to stimulate the growth and the cytotoxic potential of isolated human NK cells.

15 jun 2012

CliNK Nuevos protocolos de inmunoterapia:
cuarta reunión en el Laboratorio de Química de Coordinación (LCC, CNRS) de Toulouse

Laboratoire de Chimie de Coordination (LCC, CNRS) de Toulouse.
"El consorcio CliNK, financiado por el programa Sudoe de la UE, realizará su cuarta reunión en el Laboratorio de Química de Coordinación (LCC, CNRS) de Toulouse los días 18 y 19 de Junio de 2012, evento que ha sido organizada por la Dra. Anne-Marie Caminade. Miembros de todos los grupos de investigación participantes han confirmado su asistencia y durante dos días se pondrán al día los avances en el proyecto y se debatirá la continuación del mismo durante los seis meses restantes"

CliNK Nouveaux protocoles de l'immunothérapie: quatriéme reunion au Laboratoire de Chimie de Coordination (LCC, CNRS) de Toulouse.
"Le consortium CliNK, soutenu par le program Sudoe de la UE, effectuera sa quatriéme reunion au Laboratoire de Chimie de Coordination (LCC, CNRS) de Toulouse pendant le 18 et 19 Juin 2012, événement que a été organisé par le Dr. Anne-Marie Caminade. Membres de tous les groups de recherche que participent au consortium ont confirmé leur présence et pendant deux jours les avancements du projet vont etre mis à jour et la continuation pendant le prochaines six mois sera également discuté".

CliNK New immunotherapy protocols: fourth meeting at the Laboratory of Coordination Chemistry
(LCC, CNRS)in Toulouse.
"The CliNK consortium, financed by the UE Sudoe program, will celebrate its fourth meeting at the Laboratory of Coordination Chemistry (LCC, CNRS) in Toulouse on 18-19 June 2012, a meeting that has been organized by Dr. Anne Marie Caminade. Members of all the research groups that participate in the consortium have confirmed their assistance and during two days they will actualize the advancements in the project and they will also discuss the continuation of the project during the next six months"

12 jun 2012

Participación de representantes del equipo CliNK
en el congreso de la Society for Natural Immunity (SNI).

Miguel López-Botet y Aura Muntasell, investigadores del grupo Inmunidad e Infección del IMIM (Instituto de Investigación del Hospital del Mar) adscrito a la Universitat Pompeu Fabra (UPF), junto a Carlos Vilches, director del grupo de Histocompatibilidad e Inmunogenética del Hospital Universitario Puerta de Hierro, participaron en el congreso de la Society for Natural Immunity (SNI) celebrado en Asilomar (California 20-24 de abril), donde se concentraron los expertos internacionales en el campo de la biología de las células NK (ver resumen del programa).
El trabajo presentado por el Dr. López-Botet, seleccionado además para comunicación oral, corresponde a un estudio realizado en colaboración con la U. de San Luis Potosí, (Mexico), el Hospital Sant Joan de Déu de Barcelona y con el laboratorio del Dr. Vilches. En él se describe el impacto que la infección congénita por citomegalovirus ejerce sobre el compartimento de células NK.
La Dra. Muntasell presentó un estudio que muestra como el reconocimiento del citomegalovirus por parte de las células NK promueve un estado de pre-activación que facilita una respuesta citotóxica más eficiente frente a células infectadas por el virus.
En el trabajo presentado en formato de póster se discutieron aspectos relacionados con los mecanismos subyacentes al proceso descrito.

2 feb 2012

El proyecto CliNK del SUDOE fuera del laboratorio.

Durante esta semana el Consorcio CliNK está teniendo una actividad inusual, algunos de los miembros del equipo han salido de sus laboratorios, centros de estudio e investigación y desde el lunes día 30 de enero hasta el sábado 4 de febrero están participando en diferentes reuniones y actos de distintas ciudades europeas.
El lunes como estaba previsto fueron recibidos en Montpellier por Jean François Rossi y Martín Villalba para llevar a cavo su tercer encuentro como consorcio. Expusieron los temas que tenían previstos desde la anterior reunión poniendo en común los avances realizados y delimitando los puntos claves con la que desarrollar la estrategia a seguir durante los próximos meses.

Aprovechando la presencia en la ciudad del coordinador de uno de los equipos de CliNK, Miguel López-Botet, director del IMIM (Instituto de investigación del Parc de Salut Mar, Barcelona) y como principal investigador del grupo Receptores Inhibidores y Activadores del Sistema Inmune Innato, fue invitado a impartir una conferencia "NK CELLS in the anti-viral response" en el IRB "Institut de Recherche en Biothérapie" del Hôpital Saint-Eloi.

Luis Martínez-Lostao de CliNK en el Congreso "V International Conference BIFI 2012"
“Protein Targets: Discovery of Bioactive Compounds”

3 de Febrero a las 10 h.

Luis Martínez-Lostao, Profesor Ayudante Doctor en la Universidad de Zaragoza presentará el tema titulado "Tethering to liposomes results in a dramatic increase in Apo2L/TRAIL effectiveness on human leukemic cells" ("El anclaje a liposomas resulta en un incremento dramático de la efectividad de Apo2L/TRAIL contra células leucémicas humanas") en "The V International Conference of the Institute for Biocomputation and Physics of Complex Systems" (BIFI).

Alberto Anel de CliNK en el Congreso "V International Conference BIFI 2012"
Muerte celular inducida por la granulisina en tumores hematológicos humanos

Sábado 4 de Febrero a las 12.10 h.

Alberto Anel, Catedrático e investigador senior dentro del Grupo "Apoptosis, Inmunidad y Cáncer"  "Granulysin-induced cell death of human hematological tumors" (Muerte celular inducida por la granulisina en tumores hematológicos humanos) en "The V International Conference of the Institute for Biocomputation and Physics of Complex Systems" (BIFI).

Julián Pardo de CliNK en el Congreso "V International Conference BIFI 2012"
Células "NK" alogénicas: la evolución nos provee de una herramienta de gran eficiencia y especificidad para matar células resistentes a múltiples drogas en tumores hematológicos.

3 de Febrero a las 16.50 h.

Julián Pardo, Investigador Senior en la Fundación ARAID presentará el tema bajo el título "Allogeneic NK cells: evolution provides a highly efficient and specific tool to kill multidrug-resistant cells in hematological malignancies" (Células "NK" alogénicas: la evolución nos provee de una herramienta de gran eficiencia y especificidad para matar células resistentes a múltiples drogas en tumores hematológicos) en "The V International Conference of the Institute for Biocomputation and Physics of Complex Systems" (BIFI).

El póster de Elena Catalán "MHC class I modulation due to metabolic changes regulates tumor sensitivity to NK cells" el "V International Conference BIFI 2012"

Elena Catalán perteneciente al equipo del Consorcio CliNK es becaria pre-doctoral del Ministerio de Ciencia e Innovación y ha realizado el póster titulado "MHC class I modulation due to metabolic changes regulates tumor sensitivity to NK cells" que estará durante el "V International Conference BIFI 2012" “Protein Targets: Discovery of Bioactive Compounds”

31 ene 2012

Un congreso de la Universidad de Zaragoza sobre el desarrollo de nuevos fármacos contra el cáncer reúne a más de 150 investigadores de todo el mundo esta semana

El encuentro científico, organizado por el Instituto de Biocomputación y Física de Sistemas Complejos (BIFI), analizará también los avances frente a enfermedades raras e infecciosas.


El rector Manuel López Pérez y el consejero de Industria e Innovación, Arturo Aliaga, asisten mañana a la inauguración, que tendrá lugar a las 9.00 horas en Ibercaja-Patio de la Infanta.